Why Mushroom Supplements Can't Make Health Claims

FDA & Mushroom Supplement Regulation

29% of supplements that drew an FDA warning letter were still on sale six years later

The legal line between a supplement and a drug is unambiguous, and crossing it carries serious consequences. What is far less certain is whether anyone will notice. Mushroom supplements appear regularly in FDA enforcement actions — and the language FDA quotes is rarely as blunt as people assume.

Cohen PA et al. JAMA. 2022

80,000+

supplement products now sold in the US, up from about 4,000 when DSHEA passed in 1994

10%

of cGMP-covered supplement manufacturers FDA inspected in 2013 — 416 firms

mushroom supplement companies named in FDA warning letters between 2020 and 2025

Cohen PA et al. JAMA. 2022

View as image ↗

A mushroom supplement cannot legally claim to treat a disease. That much is settled, and has been since 1994. The reason traces to a distinction built into federal law: supplements describe how they support normal body functions; drugs treat disease. Cross that line and the product stops being a supplement.

That reclassification is not a labeling technicality. It means the company is manufacturing an unapproved drug under the Food, Drug, and Cosmetic Act. The FDA can seize the product, seek a federal injunction halting distribution, and in clear cases of knowing violation, refer for criminal prosecution.

What the law says and what happens in practice are two different questions. When researchers tracked 31 supplement products that had received FDA warning letters, only one was recalled. Nine were still available for purchase an average of six years later, and five of those nine still contained a prohibited ingredient when chemically analyzed.^[4]

The broader structure of FDA's regulatory framework for mushroom supplements is in How the FDA Regulates Mushroom Supplements: The DSHEA Framework. This article focuses on the health claims question: why the legal line exists, what the reclassification risk actually means, where the gray area is, and what the real enforcement record reveals — including the fact that the language FDA cites is usually hedged, not blunt.

Key Takeaways

Under DSHEA, mushroom supplements are legally barred from claiming to diagnose, treat, cure, or prevent any disease; a disease claim triggers reclassification of the product from supplement to unapproved drug
Making a disease claim does not just violate a labeling rule: it reclassifies the product under 21 U.S.C. §321(g)(1)(B), giving FDA authority to seize, enjoin, and criminally prosecute
The language FDA actually quotes in mushroom warning letters is overwhelmingly hedged — "potential for fighting cancer," "may be effective in combating dementia," "may contain anti-viral properties." Softening a claim does not move it out of drug territory
The US supplement market grew from roughly 4,000 products in 1994 to more than 80,000 today, now worth about $60 billion domestically, while enforcement stayed reactive (Wallace & Koturbash 2025)^[3]
FDA inspected only 416 supplement manufacturers for cGMP adherence in 2013 — about 10% of the manufacturers covered by those regulations (Starr 2015)^[1]
Implied disease claims are also prohibited: language referencing disease symptoms, or targeting a diagnosed patient population, is still a disease claim even when the disease is never named
Any label making a structure/function claim must carry this exact required text: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Why Mushroom Supplements Can't Claim to Treat Disease: The DSHEA Answer

The distinction between supplements and drugs is not arbitrary. It reflects a regulatory bargain Congress made in 1994.

Under 21 U.S.C. §343(r)(6), a dietary supplement may make structure/function claims: statements about how a product supports the structure or function of a normally operating body. "Supports healthy immune function." "Promotes mental clarity." "Helps maintain normal energy levels." These describe normal physiological processes and are permissible.

Disease claims describe something else entirely. They say the product affects a disease or medical condition: treats it, prevents it, cures it, or diagnoses it. Under 21 U.S.C. §321(g)(1)(B), any product intended for use in the treatment, cure, mitigation, or prevention of disease is a drug by legal definition. Intent is established by labeling, advertising, and context — not by the manufacturer's private characterization of what they meant.

The four verbs most often cited are diagnose, treat, cure, and prevent. But as the enforcement record below shows, fixating on those four words badly misreads how FDA actually evaluates a claim. What matters is whether the claim points at a disease, not which verb carries it there.

The Reclassification Trap: Why It's More Serious Than a Fine

Most coverage of supplement warning letters frames them as penalties for "misleading marketing." That framing significantly undersells the legal exposure.

When a mushroom supplement label says its product relieves depression, the company has not simply written an illegal sentence. They have established the intended use of their product as a drug use. Under the FDCA, that makes the product a drug. They are now manufacturing and distributing an unapproved new drug without an approved New Drug Application.

That violation sits in a separate legal category from false advertising. The FDA does not need to prove the product is harmful to act. An unapproved drug can be removed from market regardless of its safety record, because the legal requirement for drug approval was not met before marketing began.

The enforcement tools available to FDA at that point are:

Warning letter. FDA demands the company correct violations, typically within 15 business days. The letter becomes a public record.

Product seizure. Federal marshals act under judicial authorization to remove products from warehouses, distributors, and retail locations. A seizure action is distinct from a recall: the FDA initiates it, not the company.

Injunction. FDA seeks a federal court order prohibiting the company from continuing to manufacture or distribute the product. Injunctions can also restrict a company from operating in the supplement space entirely for a defined period.

Criminal prosecution. For cases involving knowing and willful violation, FDA can refer for criminal prosecution. Company owners and executives may face personal liability, not just corporate liability.

A warning letter is the lowest rung, and in practice the overwhelming majority of supplement enforcement stops there. Companies that continue making disease claims after receiving one, or that reappear under new branding with the same violations, move up the ladder.

For companies cited over ingredient safety rather than claims, the legal track is different. The Blue Forest Farms warning letter (#711990, September 11, 2025) cited Amanita muscaria products as adulterated, with FDA stating it was not aware of any basis to conclude that Amanita muscaria is Generally Recognized as Safe for use in food, and treating it as a new dietary ingredient for which no adequate safety notification had been submitted. The GRAS framework and what it means for mushroom ingredients is covered separately in GRAS Status for Mushroom Ingredients: What It Means.

Ingredient safety

Critical

Amanita muscaria is not an approved supplement ingredient

Concern

Amanita muscaria products are increasingly sold as microdose capsules, tinctures and edibles. FDA has identified published literature, adverse event reports and poison control calls describing serious central nervous system effects — including delirium, seizures, coma, respiratory depression and potentially death.

What the research says

FDA has stated it is not aware of any basis to conclude Amanita muscaria is Generally Recognized as Safe for use in food, and has issued warning letters treating these products as adulterated.

Particularly relevant for: Anyone considering Amanita muscaria products, which are legally distinct from the functional mushrooms (lion's mane, reishi, chaga, cordyceps) discussed elsewhere in this article

What to do

Do not treat Amanita muscaria as interchangeable with culinary or functional mushroom supplements. This article is general legal and regulatory information, not medical advice — discuss any supplement use with a qualified healthcare professional.

FDA warning letter #711990 to Blue Forest Farms, LLC, September 11, 2025; FDA constituent update on Amanita muscaria in food.

The Enforcement Gap: A Market That Outgrew Its Regulator

If the legal boundary is clearly defined and the consequences are severe, why do prohibited claims persist?

The answer is structural, and the numbers tell it clearly.

When DSHEA passed in 1994, roughly 600 US manufacturers were producing an estimated 4,000 supplement products. By 2000 the market had passed 29,000 products.^[2] Thirty years on, it exceeds 80,000 products and roughly $60 billion in domestic sales.^[3]

Enforcement capacity did not scale with it. In 2013, FDA inspected 416 supplement manufacturers for cGMP adherence — about 10% of the roughly 4,000 manufacturers covered by those regulations, and 2.8% of the nearly 15,000 domestic and international supplement firms registered with the agency.^[1]

The FDA's model for supplement oversight is entirely reactive. Labels are not reviewed before products reach shelves. The agency acts in response to complaints, import monitoring, targeted inspections, or its own surveillance of online marketing. There is no point in the supply chain at which a supplement company must submit its claims for FDA review before first using them.

A company can put a disease claim on a product page in January and, with meaningful probability, still be selling that product undisturbed in December.

What a warning letter actually changes

Six Years After the Letter, Most Products Were Still There

A warning letter is often described as the moment a company's risk calculation changes. The one systematic follow-up study suggests that, for a substantial minority of products, it does not.

31products received an FDA warning letter

For the prohibited stimulants BMPEA, methylsynephrine or octodrine (letters issued 2015, 2016, 2019).

1was recalled by its manufacturer

Just 3% of the products drew a voluntary recall.

9were still on sale a mean of 6 years later

29% of the cited products could still be purchased online in January 2022.

5of those 9 still contained a prohibited ingredient

56% of the still-available products tested positive on chemical analysis; 2 still contained the very ingredient that prompted the letter.

Read this carefully

These letters concerned prohibited stimulant ingredients, not disease claims, and none involved mushroom products. It is the closest systematic evidence available on what follows a warning letter — but it is adjacent evidence, not a measurement of how mushroom companies respond to claims enforcement.

Source: Cohen PA, Avula B, Katragunta K, Khan I. Recalls, Availability, and Content of Dietary Supplements Following FDA Warning Letters. JAMA. 2022;328(4):393–395.

That last finding deserves emphasis, because it complicates a comfortable assumption. It is tempting to say that a warning letter is the moment the calculation changes — that a public, documented notice of violation forces correction. The evidence available does not support stating that confidently. In the one systematic follow-up study, 29% of cited products were still purchasable roughly six years later, and more than half of those still contained at least one prohibited ingredient.^[4]

Two caveats matter. That study examined letters about prohibited stimulant ingredients, not disease claims, and none of the products were mushroom products — so it is adjacent evidence rather than a direct measurement. And the mushroom-specific record does show correction happening: of the six mushroom companies cited between 2020 and 2025, at least two received closeout letters confirming FDA considered the violations addressed.

Real Warning Letters: What Mushroom Companies Actually Said

The letters issued to mushroom supplement companies since 2020 document what prohibited claims look like in practice. Each is identified below by its FDA letter number and issue date, so every entry can be checked against FDA's public database.

The public record, 2020–2025

Six Mushroom Companies, Six FDA Warning Letters — and What FDA Actually Quoted

Each letter is identified by its FDA CMS number and issue date, so any claim below can be checked against FDA's public warning letter database. Note how little of the quoted language uses a blunt disease verb.

Half Hill Farm, Inc.

#609440Nov 3, 2020Disease claims

Products cited

Turkey Tail, Cordyceps, Lion’s Mane, Chaga and Red Reishi dual extracts

What FDA quoted

Website claims establishing intended use as a drug. FDA noted that scientific references used commercially to promote a product can themselves become evidence of intended use.

Resolution: Closed out Sep 22, 2021. A further letter (#720213) followed Mar 6, 2026.

Mushroom Revival, Inc.

#610361Dec 1, 2020Disease claims

Products cited

Cordyceps Militaris, Reishi, Mush-10

What FDA quoted

“may contain anti-viral properties” · “alleviate respiratory diseases” · “one of the most effective mushrooms for chronic viral infections”

Entia Biosciences, Inc.

#610493Jan 6, 2021Disease claims

Products cited

Mushroom-based supplement products

What FDA quoted

Marketing language FDA determined established the products’ intended use as drugs.

Brilliant Enterprises LLC

#609523Jul 20, 2021Disease claims

Products cited

Lion’s Mane, BoomChaga, CordaCex, LVL:MAX

What FDA quoted

“Relieves Depression and Anxiety” · “May Be Effective in Combating Dementia/Alzheimer’s Disease” · “Potential For Fighting Cancer” · “Anti-diabetic Effects”

Lone Star Botanicals, Inc.

#659735Nov 6, 2023Claims + cGMP

Products cited

Organic Lion’s Mane, Cordyceps and Reishi superfood powders

What FDA quoted

Drug claims cited alongside current Good Manufacturing Practice and preventive-controls violations found on facility inspection.

Resolution: Closed out Jun 25, 2024.

Blue Forest Farms, LLC

#711990Sep 11, 2025Adulteration

Products cited

Amanita Muscaria Microdose Capsules, Magic Potion Tincture, Magic Chocolate

What FDA quoted

Adulteration, not disease claims: FDA stated it is not aware of any basis to conclude Amanita muscaria is GRAS, and treated it as an unnotified new dietary ingredient.

A warning letter is an allegation of violation, not a finding of guilt by a court. Two of these six companies subsequently received closeout letters confirming FDA considered the violations addressed.

Source: FDA Inspections, Compliance, Enforcement and Criminal Investigations — Warning Letters database, letters #609440, #610361, #610493, #609523, #659735 and #711990.

Read the "what FDA quoted" column closely, because it contradicts the story usually told about supplement enforcement.

The common assumption is that companies who get cited are using flagrant, obviously-illegal language — bare disease verbs on a label. That is not what these letters show. FDA quoted Brilliant Enterprises for phrases including "Potential For Fighting Cancer Due To The Extremely High Level of Anti-oxidants," "May Be Effective in Combating Dementia/Alzheimer's Disease," "Relieves Depression and Anxiety," and "Anti-diabetic Effects." It quoted Mushroom Revival for "may contain anti-viral properties," "alleviate respiratory diseases," and "one of the most effective mushrooms for chronic viral infections."

Every one of those is hedged. "Potential for." "May be effective." "May contain." These are exactly the constructions a company adopts when it believes it is being careful.

Hedging is not a defence

What People Assume FDA Cites vs. What FDA Actually Quoted

Almost none of the language FDA quoted in these mushroom supplement letters used a bare disease verb. Every phrase on the right is hedged — and every one of them still established the product's intended use as a drug.

Commonly assumed (illustrative — not quoted)

Verbatim from the warning letter